Literature DB >> 21172722

Thrombophilic screening in young patients (< 40 years) with idiopathic ischemic stroke: a controlled study.

Francesco Dragoni1, Flavia Chiarotti, Giuseppe Rosano, Paolo Simioni, Daniela Tormene, Maria Gabriella Mazzucconi, Arturo Cafolla, Giuseppe Avvisati.   

Abstract

INTRODUCTION: Despite extensive clinical and laboratory investigations, the etiology of ischemic stroke remains unknown in approximately one third of patients.
MATERIALS AND METHODS: Thirty-four consecutive patients less than 40 years old (Males 13, Females 21, mean age 26.6 years, range 2-39) with documented ischemic stroke underwent, one year after the acute event, laboratory evaluation of antithrombin, protein C, free and total protein S, activated protein C resistance, fibrinogen, factor VII:C, homocysteine levels and antiphospholipid antibodies (APA). Moreover, prevalence of F5 R506Q, F2 G2021A and homozygosis for thermolabile variant C677T of the methylenetetrahydrofolate reductase (MTHFR) were also evaluated and compared to the results obtained in 120 normal controls.
RESULTS: Antithrombin and protein C levels resulted normal in all cases. One patient (2.9%) showed free protein S deficiency and 3 patients (8.8%) had activated protein C resistance. Homocysteine levels above 15 μmol/L were found in one patient (2.9%). APA were found in 21 patients (61.7%) and in only 2 out of 120 (1.66%) controls (OR=95.31; 95% C.I.: 18.22-667.81). The multivariate analysis selected that the presence of APA was significantly associated with an increased risk of stroke (OR=156.60; 95% C.I.: 25.99-943.47) in this cohort of patients. The combination between APA and cardiovascular risk factors determined a risk of 29-fold (OR=29.31; 95% CI: 3.28-261.69). DISCUSSION: Our data suggest that the presence of APA is associated with an increased risk of idiopathic ischemic stroke in young patients. Furthermore, also the combination of APA and cardiovascular risk factors is significantly associated with development of idiopathic ischemic stroke. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21172722     DOI: 10.1016/j.thromres.2010.11.013

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  The importance of MTHFR polymorphisms in pediatric cerebral stroke.

Authors:  Ekrem Unal; Fatma Turkan Mutlu; Musa Karakukcu
Journal:  Childs Nerv Syst       Date:  2011-10-27       Impact factor: 1.475

2.  MTHFR (C677T, A1298C), FV Leiden polymorphisms, and the prothrombin G20210A mutation in arterial ischemic stroke among young tunisian adults.

Authors:  Lamia M'barek; Salma Sakka; Fatma Meghdiche; Dhaker Turki; Khadija Maalla; Mariem Dammak; Choumous Kallel; Chokri Mhiri
Journal:  Metab Brain Dis       Date:  2021-01-05       Impact factor: 3.584

3.  Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson
Journal:  Stroke       Date:  2014-10-28       Impact factor: 7.914

4.  Classical and additional antiphospholipid antibodies in blood samples of ischemic stroke patients and healthy controls.

Authors:  Narin-Nard Carmel-Neiderman; David Tanne; Idan Goren; Pnina Rotman-Pikielny; Yair Levy
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

5.  Is the 1298A>C polymorphism in the MTHFR gene a risk factor for arterial ischaemic stroke in children? The results of meta-analysis.

Authors:  Beata Sarecka-Hujar; Ilona Kopyta; Michal Skrzypek
Journal:  Clin Exp Med       Date:  2018-02-02       Impact factor: 3.984

6.  Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients.

Authors:  Markus Alexander Thaler; Regina Feurer; Christoph Thaler; Natalie Sonntag; Michael Schleef; Ina-Christine Rondak; Holger Poppert
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.